ArticleThe Journal of clinical investigation2007
Proteinuria: is it all in the foot?
Article in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.Internal medicine (Tokyo, Japan) · 2026Article
- Research progress on multiple cell death pathways of podocytes in diabetic kidney disease.Molecular medicine (Cambridge, Mass.) · 2023Review
- Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.Liver cancer · 2023Article
- Containing anti-PLA2R IgG antibody induces podocyte injury in idiopathic membranous nephropathy.Renal failure · 2023Article
- Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease.Biomedicines · 2022Article
- The glomerular filtration barrier: a structural target for novel kidney therapies.Nature reviews. Drug discovery · 2021Review
- Development of Biomarkers and Molecular Therapy Based on Inflammatory Genes in Diabetic Nephropathy.International journal of molecular sciences · 2021Review
- Morphological analyses of nephrin expression in progressive glomerulonephropathy of common marmosets.Journal of toxicologic pathology · 2021Article
- 3D organoid-derived human glomeruli for personalised podocyte disease modelling and drug screening.Nature communications · 2018Article
- Cathepsin L activity correlates with proteinuria in chronic kidney disease in humans.International urology and nephrology · 2017Observational
- Human genetics of nephrotic syndrome and the quest for precision medicine.Current opinion in nephrology and hypertension · 2016Review
- Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models.Nature medicine · 2015Article
- Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus.Frontiers in endocrinology · 2014Review
- Glucose-induced gradual phenotypic modulation of cultured human glomerular epithelial cells may be independent of Wilms' tumor 1 (WT1).BMC cell biology · 2013Article
- HIV compromises integrity of the podocyte actin cytoskeleton through downregulation of the vitamin D receptor.American journal of physiology. Renal physiology · 2013Article
- Glomerulopathy in the KK.Cg-A(y) /J mouse reflects the pathology of diabetic nephropathy.Journal of diabetes research · 2013Article
- Podocyte biology and pathogenesis of kidney disease.Annual review of medicine · 2013Review
- Renal evaluation in women with preeclampsia.Nephron extra · 2012Article
- Cell biology and pathology of podocytes.Annual review of physiology · 2012Review
- Podocyte dysfunction in aging--related glomerulosclerosis.Frontiers in bioscience (Scholar edition) · 2011Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant advances in our understanding of the molecular structure and composition of the glomerular filtration barrier, the mechanisms underlying the presence of excess protein in the urine (proteinuria) in acquired human kidney diseases remain elusive. In a study appearing in this issue of the JCI, Sever and associates use a combination of biochemical, genetic, and in vivo approaches in mice to demonstrate a pivotal role of cathepsin L and its substrate the GTPase dynamin, in the induction of proteinuria and associated foot process effacement in glomerular podocytes (see the related article beginning on page 2095).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.